Ricardo Castro

Ms. Ricardo Castro

Ribeirão Preto Medical School - FMRP-USP
+1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
FZFabiana Albani Zambuzi
Fabiana Albani Zambuzi
PCPriscilla Mariane Cardoso-Silva
Priscilla Mariane Cardoso-Silva
RCRicardo Castro
Ricardo Castro
CFCaroline Fontanari
Caroline Fontanari
FEFlavio Emery
Flavio Emery
FFFabiani Frantz
Fabiani Frantz
Decitabine is an approved hypomethylating agent used for treating hematological malignancies. Although decitabine targets altered cells, epidrugs can trigger immunomodulatory effects, reinforcing the hypothesis of immunoregulation in treated patients. We therefore aimed to evaluate the impact of decitabine treatment on the phenotype and functions of monocytes and macrophages, which are pivotal cells of the innate immunity system. In vitro decitabine administration increased bacterial phagocytosis and IL-8 release, but impaired microbicidal activity of monocytes. In addition, during monocyte-to-macrophage differentiation, treatment promoted the M2-like profile, with increased expression of CD206 and ALOX15. Macrophages also demonstrated reduced infection control when exposed to Mycobacterium tuberculosis in vitro. However, cytokine production remained unchanged, indicating an atypical M2 macrophage. Furthermore, when macrophages were cocultured with lymphocytes, decitabine induced a reduction in the release of inflammatory cytokines such as IL-1β, TNF-α, and IFN-γ, maintaining IL-10 production, suggesting that decitabine could potentialize M2 polarization and might be considered as a therapeutic against the exacerbated immune response.

29 September 2022 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
VBVitor Leonardo Bassan
Vitor Leonardo Bassan
GBGabriel Dessotti Barretto
Gabriel Dessotti Barretto
FAFelipe Campos de Almeida
Felipe Campos de Almeida
PPPatrícia Vianna Bonini Palma
Patrícia Vianna Bonini Palma
LBLarissa Sarri Binelli
Larissa Sarri Binelli
FCFabiola Castro
Fabiola Castro

24 April 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Pedro Vieira da Silva NetoPedro Vieira da Silva Neto
Pedro Vieira da Silva Neto
Jonatan Constança Silva de CarvalhoJonatan Constança Silva de Carvalho
Jonatan Constança Silva de Carvalho
DTDiana Mota Toro
Diana Mota Toro
BOBianca T. M. Oliveira
Bianca T. M. Oliveira
JCJuçara Gastaldi Cominal
Juçara Gastaldi Cominal
CSCarlos Sorgi
Carlos Sorgi
The COVID-19 pandemic, caused by SARS-CoV-2, has significantly affected global health, with severe inflammatory responses leading to tissue damage and persistent symptoms. Macrophage-derived extracellular vesicles (EVs) are involved in the modulation of immune responses, but their involvement in SARS-CoV-2-induced inflammation and senescence remains unclear. Triggering receptors expressed on myeloid cell-1 (TREM-1) are myeloid cell receptors that amplify inflammation, described as a biomarker of the severity and mortality of COVID-19. This study investigated the composition and effects of macrophage-derived EVs stimulated by SARS-CoV-2 (MφV-EVs) on the recipient cell response. Our results, for the first time, show that SARS-CoV-2 stimulation modifies the cargo profile of MφV-EVs, enriching them with TREM-1 and miRNA-155 association, along with MMP-9 and IL-8/CXCL8. These EVs carry senescence-associated secretory phenotype (SASP) components, promote cellular senescence, and compromise antibacterial defenses upon internalization. Our findings provide evidence that MφV-EVs are key drivers of inflammation and immune dysfunction, underscoring their potential as therapeutic targets in COVID-19.